DNS 7801
Alternative Names: DNS-7801Latest Information Update: 29 Sep 2020
At a glance
- Originator Dart NeuroScience
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 29 Sep 2020 Discontinued - Phase-II for Parkinson's disease (Adjunctive treatment) in USA (PO) before September 2020
- 30 Jan 2018 Dart NeuroScience terminates the phase II PRIORITY trial due to administrative reasons in Parkinson's disease (Adjunctive treatment) in USA (PO) (NCT03306329)
- 13 Sep 2017 Phase-II clinical trials in Parkinson's disease (Adjunctive treatment) in USA (PO) (NCT03306329)